{"id":"imr-687","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Headache"},{"rate":"6%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IMR-687 is a small molecule that acts as a potent opener of the KCNQ1 potassium channel, which is involved in the regulation of cardiac repolarization.","oneSentence":"Potassium channel opener","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:51:05.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of sickle cell disease"}]},"trialDetails":[{"nctId":"NCT02998450","phase":"PHASE1","title":"A Study of IMR-687 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Cardurion Pharmaceuticals, Inc.","startDate":"2016-10-18","conditions":"Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia","enrollment":66},{"nctId":"NCT04411082","phase":"PHASE2","title":"A Study of IMR-687 in Subjects With Beta Thalassemia","status":"TERMINATED","sponsor":"Cardurion Pharmaceuticals, Inc.","startDate":"2020-10-16","conditions":"β Thalassemia","enrollment":122},{"nctId":"NCT03401112","phase":"PHASE2","title":"A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)","status":"COMPLETED","sponsor":"Cardurion Pharmaceuticals, Inc.","startDate":"2018-01-26","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT04474314","phase":"PHASE2","title":"A Study of IMR-687 in Subjects With Sickle Cell Disease","status":"TERMINATED","sponsor":"Cardurion Pharmaceuticals, Inc.","startDate":"2020-08-13","conditions":"Sickle Cell Disease","enrollment":115},{"nctId":"NCT05312021","phase":"PHASE2","title":"Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction","status":"WITHDRAWN","sponsor":"Cardurion Pharmaceuticals, Inc.","startDate":"2022-04","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":""},{"nctId":"NCT04053803","phase":"PHASE2","title":"An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imara, Inc.","startDate":"2019-05-22","conditions":"Sickle Cell Disease","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"IMR-687","genericName":"IMR-687","companyName":"Cardurion Pharmaceuticals, Inc.","companyId":"cardurion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Potassium channel opener Used for Treatment of sickle cell disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}